A pertinent topic of concern is the theoretical risk of cerebrovascular and cardiac events in patients undergoing anti-VEGF therapy, especially those who have been diagnosed with PXE [3]. This evidence concerns the gene VEGFA and pseudoxanthoma elasticum (inherited or acquired).